These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 22863482)

  • 1. [Cerebrospinal fluid biomarkers for the early diagnosis of Parkinson's disease].
    da Costa AG; Gago MF; Garrett C
    Acta Med Port; 2011 Dec; 24 Suppl 4():761-8. PubMed ID: 22863482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy.
    Ishigami N; Tokuda T; Ikegawa M; Komori M; Kasai T; Kondo T; Matsuyama Y; Nirasawa T; Thiele H; Tashiro K; Nakagawa M
    Mov Disord; 2012 Jun; 27(7):851-7. PubMed ID: 22674850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic markers for Parkinson's disease.
    Chahine LM; Stern MB
    Curr Opin Neurol; 2011 Aug; 24(4):309-17. PubMed ID: 21464716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications.
    Akhtar RS; Stern MB
    Expert Rev Neurother; 2012 Dec; 12(12):1429-38. PubMed ID: 23237350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of α-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease?
    Mollenhauer B
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S76-9. PubMed ID: 24262194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease.
    Wang ES; Sun Y; Guo JG; Gao X; Hu JW; Zhou L; Hu J; Jiang CC
    Acta Neurol Scand; 2010 Nov; 122(5):350-9. PubMed ID: 20085559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in Parkinson's disease: an update.
    Shtilbans A; Henchcliffe C
    Curr Opin Neurol; 2012 Aug; 25(4):460-5. PubMed ID: 22772875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of Parkinson's disease and Dementia with Lewy bodies.
    Henchcliffe C; Dodel R; Beal MF
    Prog Neurobiol; 2011 Dec; 95(4):601-13. PubMed ID: 21983334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The search for biomarkers in Parkinson's disease: a critical review.
    Antoniades CA; Barker RA
    Expert Rev Neurother; 2008 Dec; 8(12):1841-52. PubMed ID: 19086880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.
    Hong Z; Shi M; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Leverenz JB; Baird G; Montine TJ; Hancock AM; Hwang H; Pan C; Bradner J; Kang UJ; Jensen PH; Zhang J
    Brain; 2010 Mar; 133(Pt 3):713-26. PubMed ID: 20157014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis.
    Parnetti L; Cicognola C; Eusebi P; Chiasserini D
    Biomark Med; 2016; 10(1):35-49. PubMed ID: 26643452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia.
    Lehnert S; Jesse S; Rist W; Steinacker P; Soininen H; Herukka SK; Tumani H; Lenter M; Oeckl P; Ferger B; Hengerer B; Otto M
    Exp Neurol; 2012 Apr; 234(2):499-505. PubMed ID: 22327139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of haptoglobin and transthyretin as potential biomarkers for the preclinical diagnosis of Parkinson's disease.
    Argüelles S; Venero JL; García-Rodriguez S; Tomas-Camardiel M; Ayala A; Cano J; Machado A
    Neurochem Int; 2010 Oct; 57(3):227-34. PubMed ID: 20553985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics in Parkinson's disease: current trends, translational snags and future possibilities.
    Srivastava G; Singh K; Tiwari MN; Singh MP
    Expert Rev Proteomics; 2010 Feb; 7(1):127-39. PubMed ID: 20121482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.
    Mollenhauer B; El-Agnaf OM; Marcus K; Trenkwalder C; Schlossmacher MG
    Biomark Med; 2010 Oct; 4(5):683-99. PubMed ID: 20945981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for the early detection of Parkinson's and Alzheimer's disease.
    Berg D
    Neurodegener Dis; 2008; 5(3-4):133-6. PubMed ID: 18322370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in CSF biomarkers for Parkinson's disease.
    LeWitt P
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S49-51. PubMed ID: 22166453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases.
    Otto M; Lewczuk P; Wiltfang J
    Methods; 2008 Apr; 44(4):289-98. PubMed ID: 18374272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.